---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-007981"
form_type: "8-K"
ticker: "NUS"
cik: "0001021561"
company_name: "NU SKIN ENTERPRISES, INC."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T01:55:09.975410+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B

## Summary
- Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.
- FY2023 revenue $1.97B (-12%); adj EPS $1.85 after inventory write-off charges.
- FY2024 guidance: rev $1.73-1.87B, adj EPS $0.95-1.35; Q1 rev $400-435M, adj EPS $0.00-0.10.
- Quarterly dividend set at $0.06/share; record Feb 26, payable Mar 6, 2024.
- CSO Joseph Chang departs Mar 30; will transition to Scientific Advisory Board; role no longer executive.

## SEC filing metadata
- accession: 0001140361-24-007981
- form_type: 8-K
- ticker: NUS
- cik: 0001021561
- company_name: NU SKIN ENTERPRISES, INC.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/ef20021676_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-007981
- JSON: https://secwatch.observer/filing/0001140361-24-007981.json
- Plain text: https://secwatch.observer/filing/0001140361-24-007981.txt

## Key facts
- Earnings Releases
  NU SKIN ENTERPRISES, INC. reported Full-year 2024 results: revenue $1.73 to $1.87 billion, EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP. Guidance reaffirmed.
  - Period: Full-year 2024
  - Revenue: $1.73 to $1.87 billion
  - EPS: $0.75 to $1.15 or $0.95 to $1.35 non-GAAP
  - Guidance: reaffirmed
  - Result: guidance update
  source text: 2024 Revenue $1.73 to $1.87 billion; (12)% to (5)% • Approximately (1)% FX impact 2024 EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP
  evidence_url: https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm
- Earnings Releases
  NU SKIN ENTERPRISES, INC. reported Q1 2024 results: revenue $400 to $435 million, EPS $(0.07) to $0.03. Guidance reaffirmed.
  - Period: Q1 2024
  - Revenue: $400 to $435 million
  - EPS: $(0.07) to $0.03
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Q1 2024 Revenue $400 to $435 million; (17)% to (10)% • Approximately (3) to (2)% FX impact Q1 2024 EPS $(0.07) to $0.03 or $0.00 to $0.10 non-GAAP
  evidence_url: https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm
- Earnings Releases
  NU SKIN ENTERPRISES, INC. reported financial results for the three-month and annual periods ended December 31, 2023.
  - Period: the three-month and annual periods ended December 31, 2023
  - Result: reported results
  source text: On February 14, 2024, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2023, and certain other information.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm
- Executive change
  Joseph Chang departed as Chief Scientific Officer at NU SKIN ENTERPRISES, INC..
  - Action: stepping down
  - Role: Chief Scientific Officer
  source text: Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.